Integer (NYSE:ITGR) Cut to “Hold” at Wall Street Zen

Wall Street Zen cut shares of Integer (NYSE:ITGR) from a buy rating to a hold rating in a research report report published on Saturday.

ITGR has been the subject of a number of other research reports. KeyCorp dropped their target price on Integer from $145.00 to $133.00 and set an “overweight” rating for the company in a research report on Tuesday, October 21st. Bank of America downgraded Integer from a “buy” rating to a “neutral” rating and set a $87.00 target price for the company. in a research report on Friday. Citigroup downgraded Integer from a “buy” rating to a “neutral” rating and lowered their price objective for the company from $140.00 to $77.00 in a research report on Thursday. Wells Fargo & Company reiterated an “equal weight” rating and issued a $80.00 price objective (down previously from $132.00) on shares of Integer in a research report on Friday. Finally, Raymond James Financial reiterated an “outperform” rating and issued a $95.00 price objective (down previously from $143.00) on shares of Integer in a research report on Friday. Four analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the company. According to data from MarketBeat, Integer has an average rating of “Hold” and an average price target of $97.75.

Integer Stock Performance

NYSE:ITGR opened at $70.26 on Friday. The business has a 50 day moving average of $102.91 and a 200 day moving average of $112.13. The company has a market capitalization of $2.46 billion, a price-to-earnings ratio of 29.40, a PEG ratio of 0.57 and a beta of 0.97. Integer has a 1-year low of $66.50 and a 1-year high of $146.36. The company has a debt-to-equity ratio of 0.70, a current ratio of 3.71 and a quick ratio of 2.45.

Integer (NYSE:ITGR) last released its earnings results on Thursday, October 23rd. The medical equipment provider reported $1.79 earnings per share for the quarter, topping analysts’ consensus estimates of $1.68 by $0.11. The company had revenue of $467.69 million during the quarter, compared to the consensus estimate of $466.45 million. Integer had a return on equity of 12.84% and a net margin of 4.75%.Integer’s quarterly revenue was up 8.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.43 EPS. Integer has set its FY 2025 guidance at 6.290-6.430 EPS. On average, sell-side analysts predict that Integer will post 6.01 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Integer

A number of hedge funds and other institutional investors have recently made changes to their positions in ITGR. Alliancebernstein L.P. raised its holdings in shares of Integer by 885.1% during the second quarter. Alliancebernstein L.P. now owns 1,106,091 shares of the medical equipment provider’s stock valued at $136,016,000 after acquiring an additional 993,810 shares in the last quarter. Tributary Capital Management LLC raised its holdings in shares of Integer by 92.6% during the third quarter. Tributary Capital Management LLC now owns 499,776 shares of the medical equipment provider’s stock valued at $51,642,000 after acquiring an additional 240,226 shares in the last quarter. Nuveen LLC bought a new position in shares of Integer during the first quarter valued at approximately $17,634,000. Millennium Management LLC raised its holdings in shares of Integer by 2,408.8% during the first quarter. Millennium Management LLC now owns 123,132 shares of the medical equipment provider’s stock valued at $14,531,000 after acquiring an additional 118,224 shares in the last quarter. Finally, Viking Global Investors LP raised its holdings in shares of Integer by 9.1% during the second quarter. Viking Global Investors LP now owns 1,283,965 shares of the medical equipment provider’s stock valued at $157,889,000 after acquiring an additional 106,692 shares in the last quarter. Institutional investors own 99.29% of the company’s stock.

Integer Company Profile

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.